We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Circulating T cells: a promising biomarker of anti-PD-(L)1 therapy.
- Authors
Junlei Hou; Xuezhi Yang; Shuanglong Xie; Bo Zhu; Haoran Zha
- Abstract
Anti-PD-(L)1 therapy has shown great efficacy in some patients with cancer. However, a significant proportion of patients with cancer do not respond to it. Another unmet clinical need for anti-PD-(L)1 therapy is the dynamic monitoring of treatment effects. Therefore, identifying biomarkers that can stratify potential responders before PD-(L)1 treatment and timely monitoring of the efficacy of PD-(L)1 treatment are crucial in the clinical setting. The identification of biomarkers by liquid biopsy has attracted considerable attention. Among the identified biomarkers, circulating T cells are one of the most promising because of their indispensable contribution to anti-PD-(L)1 therapy. The present review aimed to thoroughly explore the potential of circulating T cells as biomarkers of anti-PD-(L)1 therapy and its advantages and limitations.
- Subjects
T cells; BIOMARKERS; LYMPHOCYTE subsets; MOVEMENT disorders; CANCER patients
- Publication
Frontiers in Immunology, 2024, p01
- ISSN
1664-3224
- Publication type
Article
- DOI
10.3389/fimmu.2024.1371559